| Objective:To investigate the expression ofβ-catenin and CyclinD1 in 4 groups: breast ductal hyperplasia, ductal atypical hyperplasia, ductal carcinoma in situ and breast carcinoma, furthermore, to explore the significance ofβ-catenin and CyclinD1 in cancer development and its correlations with some clinical parameters.Method:The immunohistochemical PV-9000 staining technique was performed to detect the expression ofβ-catenin and cyclinD1 in 22 cases of breast ductal hyperplasia, 22 of ductal atypical hyperplasia, 28 of ductal carcinoma in situ and 65 of breast carcinoma. Result:①The cases of breast carcinoma group in which the expression ofβ-catenin is positive is more than the cases of other 3 groups significantly(P<0.05), and the same result was found in CyclinD1(P<0.05).②The cases of double positive or negative expression ofβ-catenin and cyclinD1 in breast carcinoma(63.1%) is more than the cases ofβ-catenin single positive(42.9%)and CyclinD1 single positive(26.1%), means these two molecules have significant correlations(χ2=5.77,P<0.05).③The significant difference in the rate ofβ-catenin positive expression was found respectively in different tumor size(>2cm or≤2cm,P<0.01), in different age(>50-years-old or≤50,P<0.01),in different pathological grading(G1>G2>G3,P<0.05),in different TNM-classification tumor(class I,ⅡorⅢ,P<0.01),in different ER expression(P<0.01) and PR expression(P<0.01),but not found in different lymph node metastasis status(P>0.05).For CyclinD1,the significant difference was found in different pathological grading,in different TNM-classification tumor, in different lymph node metastasis status and in different PR expression(P<0.01), but not found in different tumor size, in different age and in different ER expression(P>0.05). Conclusion:The aberrant expression ofβ-catenin is related with the progression of breast carcinoma through activating an cyclinD1 gene and inducing the tumor cell proliferation and malignant transformation.
|
PDF Full Text Request